PR Newswire PharmaOriginal article
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
EarningsRMB341Positive
AI Analysis
Summary
Viva Biotech announced 2026 interim results with revenue of RMB1,006.5 million, up 21.0% year-over-year, driven by CDMO commercial manufacturing acceleration and AI-enhanced drug R&D capabilities.
Financial Highlights
Revenue
RMB1,006.5 million
Importance:3/10
Sentiment:
0.60
earningsCDMOrevenue growthAI in drug development
Read the original article
Published by PR Newswire Pharma on August 27, 2026 3:09 AM